Stefan D. Anker
Born
Berlin, Germany
NationalityGerman
Alma materCharité Medical School of the Humboldt University Berlin, Germany, (1987-1993) Imperial College London, UK
Known forResearching chronic and acute heart failure, clinical trials, anemia and iron-deficiency, devices in heart failure, cachexia, sarcopenia
Scientific career
FieldsCardiology, heart failure, muscle wasting, cachexia, sarcopenia, treatment development, drugs & devices, clinical trials
InstitutionsUniversity Medical Center, Göttingen, Germany

Stefan D. Anker is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany.[1] Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany.[2] The main focus of the Innovative Clinical Trials department was research in the field of chronic heart failure, including the development and clinical testing of new therapies.[3]

He studied medicine at Charité Medical School of Humboldt-University Berlin, Germany (1987-1993)[1] and completed his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998. Since then, he has had teaching appointments in several countries (UK, Germany, Australia, Italy).[4]

His particular research interests include the pathophysiology and treatment of acute and chronic heart failure (CHF), cardiac device therapy, clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy[5] in CHF, ageing, sarcopenia and cancer.[6]

Anker is a member of and serves on the Boards of several academic organisations.[7] He serves on the editorial boards of five scientific journals (including European Heart Journal[8] and European Journal of Heart Failure[9]). He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle[10] and of ESC Heart Failure, which is the first open access heart failure journal.[11]

Anker has won several prizes (including two American Heart Association Young Investigator Awards[12][13]), and has obtained a number of fellowships and grants, including two National Institutes of Health (NIH) grants (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[14]), two grants from the EU's Seventh Framework Programme for Research (FP7), and one Innovative Medicines Initiative / Horizon 2020 grant.[15]

Memberships

Anker has been a member of the German Cardiac Society and of the European Society of Cardiology (ESC) since 1995. He is currently vice president of the ESC in charge of National Cardiac Societies and Communications. He has been serving on the board of the ESC since 2012.[16] In addition, he has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006. He was HFA President between 2012 and 2014 and he currently chairs the HFA committee on regulatory affairs.[17]

Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).[18][19]

Publications

Anker has authored more than 700 original papers, reviews, and editorials. Total citations exceed 46,000, including over 50 papers with more than 200 citations. He has an h-index of 104.[20][21] Main topics are heart failure, chronic disease, cachexia and biological markers.

Selected bibliography

  1. Anker, SD; Ponikowski, P; Varney, S; et al. (April 1997). "Wasting as independent risk factor for mortality in chronic heart failure". Lancet. 349 (9058): 1050–3. doi:10.1016/S0140-6736(96)07015-8. PMID 9107242. S2CID 27285694.
  2. Anker, SD; Chua, TP; Ponikowski, P; Harrington, D; Swan, JW; Kox, WJ; Poole-Wilson, PA; Coats, AJ (1997). "Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia". Circulation. 96 (2): 526–34. doi:10.1161/01.cir.96.2.526. PMID 9244221.
  3. Niebauer, J; Volk, HD; Kemp, M; Dominguez, M; Schumann, RR; Rauchhaus, M; Poole-Wilson, PA; Coats, AJ; Anker, SD (1999). "Endotoxin and immune activation in chronic heart failure: a prospective cohort study". Lancet. 353 (9167): 1838–42. doi:10.1016/S0140-6736(98)09286-1. PMID 10359409. S2CID 34183643.
  4. Rauchhaus, M; Coats, AJ; Anker, SD (2000). "The endotoxin-lipoprotein hypothesis". Lancet. 356 (9233): 930–3. doi:10.1016/S0140-6736(00)02690-8. PMID 11036910. S2CID 27005597.
  5. Anker, SD; Negassa, A; Coats, AJ; et al. (March 2003). "Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study". Lancet. 361 (9363): 1077–83. doi:10.1016/S0140-6736(03)12892-9. PMID 12672310. S2CID 24682546.
  6. Anker, SD; Doehner, W; Rauchhaus, M; Sharma, R; Francis, D; Knosalla, C; Davos, CH; Cicoira, M; Shamim, W; Kemp, M; Segal, R; Osterziel, KJ; Leyva, F; Hetzer, R; Ponikowski, P; Coats, AJ (2003). "Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging". Circulation. 107 (15): 1991–7. doi:10.1161/01.CIR.0000065637.10517.A0. PMID 12707250. S2CID 13323584.
  7. Anker, SD; Comin Colet, J; Filippatos, G; et al. (2009). "Ferric carboxymaltose in patients with heart failure and iron deficiency". N Engl J Med. 361 (25): 2436–48. doi:10.1056/NEJMoa0908355. hdl:11268/1142. PMID 19920054. S2CID 1755624.
  8. Maisel, A; Mueller, C; Nowak, R; Peacock, WF; Landsberg, JW; Ponikowski, P; Mockel, M; Hogan, C; Wu, AH; Richards, M; Clopton, P; Filippatos, GS; Di Somma, S; Anand, I; Ng, L; Daniels, LB; Neath, SX; Christenson, R; Potocki, M; McCord, J; Terracciano, G; Kremastinos, D; Hartmann, O; von Haehling, S; Bergmann, A; Morgenthaler, NG; Anker, SD (2010). "Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial". J Am Coll Cardiol. 55 (19): 2062–76. doi:10.1016/j.jacc.2010.02.025. PMID 20447528.
  9. Koehler, F; Winkler, S; Schieber, M; Sechtem, U; Stangl, K; Böhm, M; Boll, H; Baumann, G; Honold, M; Koehler, K; Gelbrich, G; Kirwan, BA; Anker, SD (2011). "Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study". Circulation. 123 (17): 1873–80. doi:10.1161/CIRCULATIONAHA.111.018473. PMID 21444883. S2CID 11473865.
  10. Anker, SD; Koehler, F; Abraham, WT (2011). "Telemedicine and remote management of patients with heart failure". Lancet. 378 (9792): 731–9. doi:10.1016/S0140-6736(11)61229-4. PMID 21856487. S2CID 10977216.
  11. von Haehling, S; Schefold, JC; Jankowska, EA; Springer, J; Vazir, A; Kalra, PR; Sandek, A; Fauler, G; Stojakovic, T; Trauner, M; Ponikowski, P; Volk, HD; Doehner, W; Coats, AJ; Poole-Wilson, PA; Anker, SD (2012). "Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial". J Am Coll Cardiol. 59 (6): 585–92. doi:10.1016/j.jacc.2011.10.880. PMID 22300693.
  12. Homma, S; Thompson, JL; Pullicino, PM; Levin, B; Freudenberger, RS; Teerlink, JR; Ammon, SE; Graham, S; Sacco, RL; Mann, DL; Mohr, JP; Massie, BM; Labovitz, AJ; Anker, SD; Lok, DJ; Ponikowski, P; Estol, CJ; Lip, GY; Di Tullio, MR; Sanford, AR; Mejia, V; Gabriel, AP; del Valle, ML; Buchsbaum, R (2012). "Warfarin and aspirin in patients with heart failure and sinus rhythm". N Engl J Med. 366 (20): 1859–69. doi:10.1056/NEJMoa1202299. PMC 3723382. PMID 22551105.
  13. Ponikowski, P; van Veldhuisen, DJ; Comin-Colet, J; Ertl, G; Komajda, M; Mareev, V; McDonagh, T; Parkhomenko, A; Tavazzi, L; Levesque, V; Mori, C; Roubert, B; Filippatos, G; Ruschitzka, F; Anker, SD (2015). "Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†". Eur Heart J. 36 (11): 657–68. doi:10.1093/eurheartj/ehu385. PMC 4359359. PMID 25176939.

Consensus meetings and guidelines

Anker has participated in and chaired several consensus meeting and guidelines committees:

  1. Chair, ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. (Anker et al., Clin Nutr 2009)
  2. Co-chair, Consensus Group “The definition of Cachexia” (Evans et al., Clinical Nutrition 2008)[22]
  3. AHA Consensus Group “State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association.” (Riegel et al., Circulation 2009)[23]
  4. ADQI 7 Consensus Group “Cardio-Renal Syndromes” (Ronco et al., Eur Heart J 2010)[24]
  5. Co-chair, Consensus Group “Endpoints for Cachexia Trials & Nutrition for Cachexia and Sarcopenia” (Morley et al., JAMDA 2010)[25]
  6. Nutritional recommendations for the management of sarcopenia. Co-chair. (Morley el al., JAMDA 2010)[26]
  7. “Definition and classification of cancer cachexia” (Fearon et al. Lancet Oncol 2011)[27]
  8. ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (McMurray et al., EHJ 2012)[28]
  9. HFA/WGTE of ESC Consensus on thromboembolism & anti-thrombotic therapy in heart failure with sinus rhythm (Lip et al. Eur J HF 2012)[29]
  10. ESH/ESC Guidelines for the management of arterial hypertension. Reviewer. (Mancia et al. EHJ 2013)[30]
  11. ESC/EASD Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. (Ryden et al. EHJ 2013)[31]
  12. SC/ESA 2014 Guidelines on non-cardiac surgery: cardiovascular assessment and management. (Kristensen et al. EHJ 2014)[32]
  13. Reporting on patient reported outcomes in cardiovascular trials – Position statement of the ESC cardiovascular round table. (Anker et al. EHJ 2014)[33]
  14. ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (Ponikowski et al., EHJ 2016)[34]
  15. Co-chair, Consensus Group “International Cachexia Definition – Update 2016” (ongoing)

Research

Stefan Anker has been a member of more than 30 international clinical trial steering committees, chairing or co-chairing more than 10 (including the FAIR-HF,[35] TIM-HF,[36] BACH,[37] AUGMENT-HF,[38] ACT-ONE,[39] RESHAPE-HF2,[40] IMPULSE-HF,[41] FAIR-HF2,[42][43] Fair-HFpEF,[43] EMPORER-HFpEF trials[44]). He served in several data and safety monitoring boards (chairing five) and end-point committees (chairing three).[15] In 2015 and again in 2016, he was named in the Thomson Reuters Highly Cited Researchers list.[45]

Honors and awards

[46]

  • 22/10/1998: "Ehrenmedaille der Charité Berlin" (honorary medal of Charité Medical School, Berlin)
  • 11/1998: Runner-up; Samuel A. Levine Young Investigator Award [YIA] (Clinical Cardiology) of the AHA for the paper: Niebauer J, Poole-Wilson PA, Coats AJS, Anker SD. Endotoxin and immune activation in chronic heart failure: proof of concept.
  • 3/1999: 2nd Prize; Young Investigator Award (Clinical Cardiology) of the ACC for the paper: Ponikowski P, Anker SD, Coats AJS. Oscilatory breathing patterns during the wakefulness in patients with chronic heart failure: clinical and prognostic implications.
  • 8/2000: 3rd Prize; YIA Clinical Cardiology of the European Society of Cardiology for the paper: Anker SD, Negassa A, Coats AJS, Poole-Wilson PA, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the impact of treatment with ACE inhibitors.
  • 11/2000: 1st Prize; Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Sharma R, Coats AJS, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure.
  • 2/2001: GlaxoSmithKline Respiratory Clinical Research Award (£38,358)
  • 5/2006: Animal protection research prize (22,000 EUR) (together with Dr. Springer)
  • 11/2006: 1st Prize; Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Okonko D, Poole-Wilson PA, Anker SD, Ponikowski P. Intravenous iron therapy in patients with chronic heart failure with and without anemia[47]
  • 6/2007: 1st Prize; Young Investigator Award of the European HF Association for the paper: Okonko D, Anker SD, Poole-Wilson PA. Epo and inflammatory cytokines in patients with chronic heart failure – mechanistic studies.
  • 10/2011: Storz German Telemedicine Award 2011 for TIM-HF (together with Prof. Köhler)
  • 25/10/2018 : Prof. Dr. Stefan Anker and Prof. Dr. Piotr Ponikowski from Wrocław Medical University have received the 2018 Copernicus Award from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the Fundacja na rzecz Nauki Polskiej (FNP, Foundation for Polish Science) for their services to German-Polish research collaboration. The jury appointed jointly by the DFG and the FNP selected the two researchers for their long-standing and distinguished collaboration in heart failure research. Their contributions are considered to have led to a better understanding of the pathophysiology of heart failure as well as new treatment strategies for the disease. The Copernicus Award was presented on 25 October 2018 in Berlin by the presidents of the DFG and the FNP, Prof. Dr. Peter Strohschneider and Prof. Dr. Maciej Żylicz.[48]

References

  1. 1 2 "BCRT / Single News / Berlin-Brandenburger Centrum für Regenerative Therapien". www.b-crt.de (in German). Retrieved 2017-10-04.
  2. ↑ "Universitätsmedizin Göttingen - Scientific staff". www.herzzentrum-goettingen.de. Retrieved 2017-05-17.
  3. ↑ "Universitätsmedizin Göttingen - Innovative Clinical Trials". www.herzzentrum-goettingen.de. Retrieved 2017-05-17.
  4. ↑ "ICI Meeting 2016 | Staff Members | Stefan D. Anker | Innovations". Retrieved 2017-05-17.
  5. ↑ "This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know". Prevention. 2017-09-27. Retrieved 2017-10-04.
  6. ↑ "Journal of Cachexia, Sarcopenia and Muscle". Wiley Online Library.
  7. ↑ "Journal of Cachexia, Sarcopenia and Muscle". doi:10.1007/13539.2190-6009. PMC 5989872. {{cite journal}}: Cite journal requires |journal= (help)
  8. ↑ European Heart Journal, https://academic.oup.com/eurheartj/pages/Editorial_Board
  9. ↑ "European Journal of Heart Failure". doi:10.1002/(ISSN)1879-0844. S2CID 115560449.
  10. ↑ "Home". www.jcsm.info. Retrieved 2017-05-17.
  11. ↑ ESC Heart Failure, http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2055-5822
  12. ↑ AHA Samuel A Levine Young Investigator Award (Clinical Cardiology) 1st Prize for the paper: Sharma R, Coats AJS, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure, November 2000.
  13. ↑ AHA Samuel A Levine Young Investigator Award (Clinical Cardiology) 1st Prize; for the paper: Okonko D, Poole-Wilson PA, Anker SD, Ponikowski P. Intravenous iron therapy in patients with chronic heart failure with and without anemia, November 2006.
  14. ↑ Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial, https://clinicaltrials.gov/ct2/show/NCT00041938
  15. 1 2 "HFA Career Cafe 2017". www.escardio.org. Retrieved 2017-05-17.
  16. ↑ "ESC Board". www.escardio.org. Retrieved 2017-05-17.
  17. ↑ "Committees and Study Groups of the Heart Failure Association of the ESC". www.escardio.org. Retrieved 2017-05-17.
  18. ↑ "Details of the SCWD board members". Sarcopenia, Cachexia and Wasting Disorders. Retrieved 2017-05-17.
  19. ↑ "SCWD - Sarcopenia, Cachexia and Wasting Disorders". Sarcopenia, Cachexia and Wasting Disorders. Retrieved 2017-05-17.
  20. ↑ Search Results for author Anker SD on PubMed.
  21. ↑ Scopus, March 2017, https://www.scopus.com/authid/detail.uri?authorId=56223993400
  22. ↑ Evans, William J.; Morley, John E.; Argilés, Josep; Bales, Connie; Baracos, Vickie; Guttridge, Denis; Jatoi, Aminah; Kalantar-Zadeh, Kamyar; Lochs, Herbert (2008-12-01). "Cachexia: a new definition". Clinical Nutrition (Edinburgh, Scotland). 27 (6): 793–799. doi:10.1016/j.clnu.2008.06.013. ISSN 1532-1983. PMID 18718696. S2CID 206821612.
  23. ↑ Riegel, Barbara; Moser, Debra K.; Anker, Stefan D.; Appel, Lawrence J.; Dunbar, Sandra B.; Grady, Kathleen L.; Gurvitz, Michelle Z.; Havranek, Edward P.; Lee, Christopher S. (2009-09-22). "State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association". Circulation. 120 (12): 1141–1163. CiteSeerX 10.1.1.335.9667. doi:10.1161/CIRCULATIONAHA.109.192628. ISSN 1524-4539. PMID 19720935. S2CID 6973440.
  24. ↑ Ronco, Claudio; McCullough, Peter; Anker, Stefan D.; Anand, Inder; Aspromonte, Nadia; Bagshaw, Sean M.; Bellomo, Rinaldo; Berl, Tomas; Bobek, Ilona (2017-05-17). "Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative". European Heart Journal. 31 (6): 703–711. doi:10.1093/eurheartj/ehp507. ISSN 0195-668X. PMC 2838681. PMID 20037146.
  25. ↑ Argilés, Josep M.; Anker, Stefan D.; Evans, William J.; Morley, John E.; Fearon, Ken C. H.; Strasser, Florian; Muscaritoli, Maurizio; Baracos, Vicky E. (2010-05-01). "Consensus on cachexia definitions". Journal of the American Medical Directors Association. 11 (4): 229–230. doi:10.1016/j.jamda.2010.02.004. ISSN 1538-9375. PMID 20439040.
  26. ↑ Morley, John E.; Argiles, Josep M.; Evans, William J.; Bhasin, Shalender; Cella, David; Deutz, Nicolaas E. P.; Doehner, Wolfram; Fearon, Ken C. H.; Ferrucci, Luigi (2017-05-17). "Nutritional Recommendations for the Management of Sarcopenia". Journal of the American Medical Directors Association. 11 (6): 391–396. doi:10.1016/j.jamda.2010.04.014. ISSN 1525-8610. PMC 4623318. PMID 20627179.
  27. ↑ Fearon, Kenneth; Strasser, Florian; Anker, Stefan D.; Bosaeus, Ingvar; Bruera, Eduardo; Fainsinger, Robin L.; Jatoi, Aminah; Loprinzi, Charles; MacDonald, Neil (2011-05-01). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. 12 (5): 489–495. doi:10.1016/S1470-2045(10)70218-7. ISSN 1474-5488. PMID 21296615.
  28. ↑ McMurray, John J. V.; Adamopoulos, Stamatis; Anker, Stefan D.; Auricchio, Angelo; Böhm, Michael; Dickstein, Kenneth; Falk, Volkmar; Filippatos, Gerasimos; Fonseca, Cândida (2012-07-01). "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC". European Heart Journal. 33 (14): 1787–1847. doi:10.1093/eurheartj/ehs104. ISSN 1522-9645. PMID 22611136.
  29. ↑ Lip, Gregory Y. H.; Ponikowski, Piotr; Andreotti, Felicita; Anker, Stefan D.; Filippatos, Gerasimos; Homma, Shunichi; Morais, Joao; Pullicino, Patrick; Rasmussen, Lars H. (2012-07-01). "Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis". European Journal of Heart Failure. 14 (7): 681–695. doi:10.1093/eurjhf/hfs073. ISSN 1879-0844. PMID 22611046. S2CID 20956860.
  30. ↑ Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Böhm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy (2013-07-01). "2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)". European Heart Journal. 34 (28): 2159–2219. doi:10.1093/eurheartj/eht151. hdl:1854/LU-4127523. ISSN 1522-9645. PMID 23771844.
  31. ↑ Authors/Task Force Members; Rydén, Lars; Grant, Peter J.; Anker, Stefan D.; Berne, Christian; Cosentino, Francesco; Danchin, Nicolas; Deaton, Christi; Escaned, Javier (2013-10-01). "ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)". European Heart Journal. 34 (39): 3035–3087. doi:10.1093/eurheartj/eht108. ISSN 1522-9645. PMID 23996285.
  32. ↑ Kristensen, Steen Dalby; Knuuti, Juhani; Saraste, Antti; Anker, Stefan; Bøtker, Hans Erik; Hert, Stefan De; Ford, Ian; Gonzalez-Juanatey, Jose Ramón; Gorenek, Bulent (2014-09-14). "2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)". European Heart Journal. 35 (35): 2383–2431. doi:10.1093/eurheartj/ehu282. ISSN 1522-9645. PMID 25086026.
  33. ↑ Anker, Stefan D.; Agewall, Stefan; Borggrefe, Martin; Calvert, Melanie; Jaime Caro, J.; Cowie, Martin R.; Ford, Ian; Paty, Jean A.; Riley, Jillian P. (2014-08-07). "The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials". European Heart Journal. 35 (30): 2001–2009. doi:10.1093/eurheartj/ehu205. ISSN 1522-9645. PMID 24904027.
  34. ↑ Ponikowski, Piotr; Voors, Adriaan A.; Anker, Stefan D.; Bueno, Héctor; Cleland, John G. F.; Coats, Andrew J. S.; Falk, Volkmar; González-Juanatey, José Ramón; Harjola, Veli-Pekka (2016-07-14). "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC". European Heart Journal. 37 (27): 2129–2200. doi:10.1093/eurheartj/ehw128. ISSN 1522-9645. PMID 27206819.
  35. ↑ LLC, Peripheral Brain. "FAIR-HF - Wiki Journal Club". www.wikijournalclub.org. Retrieved 2017-05-17.
  36. ↑ Koehler, Friedrich (2010). "Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design". European Journal of Heart Failure. 12 (12): 1354–1362. doi:10.1093/eurjhf/hfq199. PMID 21098580. S2CID 32860744.
  37. ↑ "Biomarkers in Acute Heart Failure - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 30 July 2008. Retrieved 2017-05-17.
  38. ↑ Anker, Stefan D.; Coats, Andrew J. S.; Cristian, Gabriel; Dragomir, Dinu; Pusineri, Enrico; Piredda, Massimo; Bettari, Luca; Dowling, Robert; Volterrani, Maurizio (2015-09-07). "A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)". European Heart Journal. 36 (34): 2297–2309. doi:10.1093/eurheartj/ehv259. ISSN 1522-9645. PMC 4561351. PMID 26082085.
  39. ↑ Rosenfield, Kenneth; Matsumura, Jon S.; Chaturvedi, Seemant; Riles, Tom; Ansel, Gary M.; Metzger, D. Chris; Wechsler, Lawrence; Jaff, Michael R.; Gray, William (2016-03-17). "Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis". New England Journal of Medicine. 374 (11): 1011–1020. doi:10.1056/NEJMoa1515706. ISSN 0028-4793. PMID 26886419.
  40. ↑ "A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-05-17.
  41. ↑ "Impulse Dynamics announced the first enrollment in the IMPULSE-HF European Randomized Efficacy Study - INT". www.impulse-dynamics.com. Retrieved 2017-05-17.
  42. ↑ "Clinical Trials Register". www.clinicaltrialsregister.eu. Retrieved 2017-05-17.
  43. 1 2 "Universitätsmedizin Göttingen - Innovative Clinical Trials". www.herzzentrum-goettingen.de. Retrieved 2017-05-17.
  44. ↑ "EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-05-17.
  45. ↑ "HCR Clarivate Analytics". Retrieved 2017-05-17.
  46. ↑ http://www.circulation.or.kr/workshop/2016spring/file/CV_Stefan%20Anker.pdf
  47. ↑ http://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319457.pdf
  48. ↑ "Copernicus Award 2018 for Stefan Anker". Retrieved 2018-11-08.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.